(NASDAQ: STOK) Stoke Therapeutics's forecast annual revenue growth rate of -53.19% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 89.16%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.7%.
Stoke Therapeutics's revenue in 2025 is $199,894,000.On average, 5 Wall Street analysts forecast STOK's revenue for 2025 to be $10,071,217,454, with the lowest STOK revenue forecast at $9,884,906,233, and the highest STOK revenue forecast at $10,420,824,981. On average, 4 Wall Street analysts forecast STOK's revenue for 2026 to be $1,496,079,106, with the lowest STOK revenue forecast at $876,758,688, and the highest STOK revenue forecast at $1,917,909,630.
In 2027, STOK is forecast to generate $2,832,314,144 in revenue, with the lowest revenue forecast at $1,424,732,868 and the highest revenue forecast at $4,676,959,626.